Lupin and Boehringer Ingelheim inked a licensing, development and commercialisation agreement in 2019 for the Indain company#39;s novel oncology compound for difficult-to-treat cancers.from Moneycontrol Business News https://ift.tt/3wFaSa7
Lupin and Boehringer Ingelheim inked a licensing, development and commercialisation agreement in 2019 for the Indain company#39;s novel oncology compound for difficult-to-treat cancers.
Comments
Post a Comment